Foresight Acquisition Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FORE research report →
Price Chart
About the company
Foresight Acquisition Corp. presently conducts no significant commercial activities. The firm's core objective is to finalize a business combination, such as a merger, an exchange of equity, an acquisition of assets, a stock buyout, a corporate restructuring, or another strategic partnership with one or more enterprises.
- CEO
- Michael P. Balkin
- IPO
- 2021
- HQ
- Chicago, IL, US
Get TickerSpark's AI analysis on FORE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.31B
- P/E
- -0.07
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.05
- EV/EBITDA
- 37.96
- Div Yield
- 0.00%
- Gross Margin
- 57.69%
- Op Margin
- -5.24%
- Net Margin
- -3.30%
- ROE
- 171.75%
- ROIC
- -23.42%
Latest fiscal year · YoY change
- Revenue
- $1.46B-2.8%
- Gross Profit
- $0+0.0%
- Op Income
- $0
- Net Income
- $-319,036,000-5.8%
- EPS
- $-45.26-4714.9%
- OCF Growth
- +17.2%
- FCF Growth
- +17.2%
- 52W High
- $10.17
- 52W Low
- $8.85
- 50D MA
- $9.88
- 200D MA
- $9.85
- Beta
- 0.00
- RSI (14)
- 41
- Avg Volume
- 304.62K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
P3 Health Partners posted a strong Q3 with $21 million of Adjusted EBITDA, raised full-year 2026 guidance, and said its medical-cost and quality initiatives are starting to show through.· November 9, 2026
- Q3 Adjusted EBITDA was $21 million, and the company lifted full-year 2026 Adjusted EBITDA guidance to $90 million-$110 million.
- Revenue rose to approximately $396 million from $345 million a year ago, while medical margin was approximately $44 million and medical loss ratio was approximately 90.6% after adjustments.
- Underlying Q3 Adjusted EBITDA was approximately $10 million after removing about $7 million of favorable medical margin from the CMS ACO reconciliation and about $5 million of non-cash income from an ACO liability release.
- Management said year-to-date Medicare Advantage medical expense is 0.7% below the full-year 2025 level on a normalized basis, though Q3 cost trend stepped up, especially in outpatient and professional services.
- The company highlighted a $200 million pool of identified value creation across clinical execution, payer economics, and operating efficiency, with more clarity promised early in 2027.
P3 reported third-quarter revenue of approximately $396 million, up from $345 million in the prior-year quarter, a 15% increase. Adjusted EBITDA was $21 million versus an Adjusted EBITDA loss of approximately $46 million in Q3 2025; year-to-date Adjusted EBITDA was $101 million versus a loss of approximately $85 million in the same period last year. Medical claims expense was approximately $322 million, medical margin was approximately $44 million, and medical loss ratio was approximately 90.6% after adjusting for favorable prior-period items. Cash and cash equivalents ended the quarter at approximately $44 million. For full-year 2026, the company raised Adjusted EBITDA guidance to $90 million-$110 million, with the midpoint increased to $100 million.
Aric Coffman framed the quarter as evidence that the company’s multi-year operational changes are working, pointing to stronger utilization management, quality execution, and medical cost control. He emphasized that the business is being built around four priorities: medical cost management, quality and burden-of-illness documentation, disciplined growth, and improved operations through people, process, and technology. He also stressed that growth will be capital-light and deliberate, with Nebraska presented as the template for entering new markets.
Leif Pedersen said Q3 Adjusted EBITDA was $21 million, but about $7 million came from favorable medical margin tied to the 2025 CMS ACO reconciliation and about $5 million from a non-cash liability release, leaving underlying Q3 Adjusted EBITDA at roughly $10 million. He noted revenue of approximately $396 million, medical claims expense of approximately $322 million, medical margin of approximately $44 million, and medical loss ratio of approximately 90.6% after adjustments. He also said adjusted operating expense was approximately $35 million, cash was approximately $44 million, and the company is balancing liquidity with continued investment in clinical and data capabilities while raising full-year EBITDA guidance to $90 million-$110 million.
Analysts focused on what drives the 2027 setup, whether there are one-time items in the outlook, and how much of the $200 million of identified opportunity is tied to existing members versus new growth. Management said it will give more detail after open enrollment and when it issues 2027 guidance, and Leif described the $200 million as a multi-year realization across three buckets: clinical execution, provider economics, and operating efficiency. On cost trend, management said Q3 pressure came mainly from the Part B side and that Nevada saw some of the increased outpatient and professional-services costs. They also said conversations with potential plan partners are active, with more than 60 mid-sized Medicare Advantage plans facing similar pressures and looking for solutions.
The company said its clinical and operational work is now embedded and delivering, with utilization management and quality both at their strongest quarters of the year. Management believes its medical-cost trend remains below peers, year-to-date medical expense is still favorable versus 2025 on a normalized basis, and the business has generated positive underlying EBITDA in each of the first three quarters of 2026. Leadership also pointed to active plan-partner discussions and a $200 million opportunity set already identified within the existing book of business.
Management acknowledged Q3 medical-cost pressure, especially in outpatient and professional services and particularly in Nevada, and said the quarter’s reported earnings benefited from one-time items. Cash was only approximately $44 million at quarter-end, so liquidity remains something they are actively managing. The company also said there is not yet full clarity on 2027 earnings timing or enrollment outcomes, and the $200 million of value creation is expected to be realized over multiple years rather than immediately.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 5.7%
- Shares Outstanding
- 243.60M
- Float Shares
- 13.90M
of shares held by institutions
89 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Omni Partners Us LLC | 662.94K | ▲ 457.04K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 4, 21 | WASSON GREGORY D | other | 6,843,525 |
| Oct 4, 21 | WASSON GREGORY D | other | 6,843,525 |
| Oct 4, 21 | GAMACHE BRIAN R | other | 25,000 |
| Oct 4, 21 | GAMACHE BRIAN R | other | 25,000 |
| Feb 12, 21 | WASSON GREGORY D | buy | 682,500 |
| Feb 9, 21 | GAMACHE BRIAN R | other | 0 |
| Feb 9, 21 | WASSON GREGORY D | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FORE coverage
Recent articles, reports, and earnings notes.
No research on FORE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FORE report →FORE Awards New Grants to Strengthen Community-Based Responses to the Opioid and Overdose Crisis
globenewswire.com · Jun 24
Sun Cruiser and G/FORE Elevate Golf Course Style with New Limited-Edition Apparel Collection
globenewswire.com · Jun 4
FORE Biotherapeutics to Participate in the Wells Fargo Virtual Private Biotech Symposium
businesswire.com · Dec 5
P3 Health Partners Announces November Conference Schedule and Virtual Investor Day in Advance of Planned Closing of Business Combination with Foresight Acquisition Corp.
globenewswire.com · Nov 5
P3 Health Partners Sets September 2021 Virtual Conference Schedule
accesswire.com · Sep 2
Moore Kuehn Encourages FMBI, LWAC, LEGO and FORE Investors to Contact Law Firm
prnewswire.com · Jun 21
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Foresight Acquisition Corp. - FORE
prnewswire.com · Jun 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.